CN115697385A - 一种治疗脊髓性肌萎缩症的方法和药物 - Google Patents
一种治疗脊髓性肌萎缩症的方法和药物 Download PDFInfo
- Publication number
- CN115697385A CN115697385A CN202080099318.3A CN202080099318A CN115697385A CN 115697385 A CN115697385 A CN 115697385A CN 202080099318 A CN202080099318 A CN 202080099318A CN 115697385 A CN115697385 A CN 115697385A
- Authority
- CN
- China
- Prior art keywords
- plasminogen
- sma
- mice
- pathway activator
- plasmin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/484—Plasmin (3.4.21.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
Abstract
一种治疗脊髓性肌萎缩症(SMA)的方法,包括给药受试者治疗有效量的纤溶酶原途径激活剂;以及用于治疗脊髓性肌萎缩症的包含纤溶酶原途径激活剂的药物组合物、制品和试剂盒。
Description
PCT国内申请,说明书已公开。
Claims (15)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2020089631 | 2020-05-11 | ||
CNPCT/CN2020/089631 | 2020-05-11 | ||
PCT/CN2020/129461 WO2021227417A1 (zh) | 2020-05-11 | 2020-11-17 | 一种治疗脊髓性肌萎缩症的方法和药物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115697385A true CN115697385A (zh) | 2023-02-03 |
Family
ID=78525998
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202080099318.3A Pending CN115697385A (zh) | 2020-05-11 | 2020-11-17 | 一种治疗脊髓性肌萎缩症的方法和药物 |
CN202180034399.3A Pending CN115551535A (zh) | 2020-05-11 | 2021-05-11 | 一种治疗脊髓性肌萎缩症的方法和药物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202180034399.3A Pending CN115551535A (zh) | 2020-05-11 | 2021-05-11 | 一种治疗脊髓性肌萎缩症的方法和药物 |
Country Status (8)
Country | Link |
---|---|
US (2) | US20230181699A1 (zh) |
EP (2) | EP4140498A4 (zh) |
JP (2) | JP2023525257A (zh) |
KR (2) | KR20230005298A (zh) |
CN (2) | CN115697385A (zh) |
CA (2) | CA3182911A1 (zh) |
TW (2) | TW202142256A (zh) |
WO (2) | WO2021227417A1 (zh) |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US20020165147A1 (en) * | 1996-10-11 | 2002-11-07 | Manuel Yepes | Brain-associated inhibitor of tissue-type plasminogen activator |
US6372473B1 (en) * | 1997-05-28 | 2002-04-16 | Human Genome Sciences, Inc. | Tissue plasminogen activator-like protease |
US20030219431A1 (en) * | 2002-05-24 | 2003-11-27 | Empire Pharmaceuticals, Inc. | Treatment of neuronal and neurological damage associated with spinal cord injury |
AU2005238464B2 (en) * | 2004-04-22 | 2011-01-27 | Grifols Therapeutics Inc. | Recombinantly modified plasmin |
JP2009528290A (ja) * | 2006-02-27 | 2009-08-06 | ワイス | 筋肉病の処置のためのpai−1阻害剤 |
AU2008331545B2 (en) * | 2007-11-29 | 2014-01-16 | Grifols Therapeutics Inc. | Recombinantly modified plasmin |
WO2009146178A1 (en) * | 2008-04-15 | 2009-12-03 | President And Fellows Of Harvard College | Angiogenin and amyotrophic lateral sclerosis |
CN102154253A (zh) | 2011-01-06 | 2011-08-17 | 郑州大学 | 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途 |
RS58326B1 (sr) * | 2011-05-04 | 2019-03-29 | Rhizen Pharmaceuticals S A | Nova jedinjenja kao modulatori proteinskih kinaza |
US20140212405A1 (en) * | 2013-01-28 | 2014-07-31 | 2294719 Ontario Limited | Fibrinolytic/Proteolytic Treatment of Myofacial and Neuropathic Pain and Related Conditions |
ES2961967T3 (es) * | 2015-12-18 | 2024-03-14 | Talengen Int Ltd | Plasminógeno para su uso en el tratamiento de la angiocardiopatía diabética |
CN108210917A (zh) * | 2016-12-15 | 2018-06-29 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗肥胖症的方法和药物 |
-
2020
- 2020-11-17 EP EP20935975.1A patent/EP4140498A4/en active Pending
- 2020-11-17 JP JP2022567202A patent/JP2023525257A/ja active Pending
- 2020-11-17 CA CA3182911A patent/CA3182911A1/en active Pending
- 2020-11-17 WO PCT/CN2020/129461 patent/WO2021227417A1/zh unknown
- 2020-11-17 CN CN202080099318.3A patent/CN115697385A/zh active Pending
- 2020-11-17 US US17/924,617 patent/US20230181699A1/en active Pending
- 2020-11-17 KR KR1020227041422A patent/KR20230005298A/ko unknown
-
2021
- 2021-02-08 TW TW110104801A patent/TW202142256A/zh unknown
- 2021-05-11 TW TW110116986A patent/TWI811675B/zh active
- 2021-05-11 KR KR1020227040829A patent/KR20230004752A/ko not_active Application Discontinuation
- 2021-05-11 WO PCT/CN2021/093039 patent/WO2021228086A1/zh unknown
- 2021-05-11 CA CA3183106A patent/CA3183106A1/en active Pending
- 2021-05-11 JP JP2022567201A patent/JP2023525256A/ja active Pending
- 2021-05-11 EP EP21803874.3A patent/EP4144364A4/en not_active Withdrawn
- 2021-05-11 US US17/924,620 patent/US20230190891A1/en active Pending
- 2021-05-11 CN CN202180034399.3A patent/CN115551535A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
TW202200192A (zh) | 2022-01-01 |
JP2023525257A (ja) | 2023-06-15 |
JP2023525256A (ja) | 2023-06-15 |
CA3183106A1 (en) | 2021-11-18 |
KR20230004752A (ko) | 2023-01-06 |
KR20230005298A (ko) | 2023-01-09 |
WO2021228086A1 (zh) | 2021-11-18 |
CA3182911A1 (en) | 2021-11-18 |
US20230190891A1 (en) | 2023-06-22 |
EP4144364A4 (en) | 2023-11-22 |
TWI811675B (zh) | 2023-08-11 |
CN115551535A (zh) | 2022-12-30 |
TW202142256A (zh) | 2021-11-16 |
US20230181699A1 (en) | 2023-06-15 |
EP4140498A1 (en) | 2023-03-01 |
EP4144364A1 (en) | 2023-03-08 |
EP4140498A4 (en) | 2023-11-01 |
WO2021227417A1 (zh) | 2021-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6749412B2 (ja) | 糖尿病性神経損傷及びその関連疾患を予防または治療するための方法 | |
WO2021143906A1 (zh) | 一种治疗神经损伤及其相关病症的方法 | |
WO2021228086A1 (zh) | 一种治疗脊髓性肌萎缩症的方法和药物 | |
TWI787767B (zh) | 一種治療亨廷頓病的方法和藥物 | |
WO2021190561A1 (zh) | 一种治疗帕金森病的方法和药物 | |
CN111905103A (zh) | 一种治疗肌萎缩侧索硬化的方法和药物 | |
TWI788779B (zh) | 一種治療病毒性肺炎的方法和藥物 | |
WO2020228681A1 (zh) | 一种治疗肌萎缩侧索硬化的方法和药物 | |
WO2021190558A1 (zh) | 一种治疗阿尔茨海默病的方法和药物 | |
WO2021170099A1 (zh) | 一种预防和治疗血压异常病症的方法和药物 | |
TW202408566A (zh) | 一種治療神經損傷及其相關病症的方法 | |
TW202228766A (zh) | 一種治療神經損傷及其相關病症的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |